Hydrolysis in pharmaceutical formulations

Pharmaceutical Development and Technology

Volumn 7, Issue 2, 2002, Pages 113-146

  Waterman, Kenneth C ^a   Adami, Roger C ^a   Alsante, Karen M ^a   Antipas, Amy S ^a   Arenson, Dan R ^a   Carrier, Rebecca ^a   Hong, Jinyang ^a   Landis, Margaret S ^a   Lombardo, Franco ^a   Shah, Jaymin C ^a   Shalaev, Evgenyi ^a   Smith, Scott W ^a   Wang, Hai ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATROPINE; CHLORAMBUCIL; CHLORAMPHENICOL; CHLORDIAZEPOXIDE; DIAZEPAM; ERYTHROMYCIN; OXAZEPAM; PARACETAMOL; PHENOBARBITAL;

CATALYSIS; COMPUTER MODEL; CONTROLLED DRUG RELEASE; CRYSTAL STRUCTURE; DRUG DEGRADATION; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG HYDROLYSIS; DRUG STABILITY; DRUG STRUCTURE; LYOPHILISATE; PRIORITY JOURNAL; REVIEW;

BUFFERS; CATALYSIS; CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG PACKAGING; DRUG STABILITY; EXCIPIENTS; HYDROGEN-ION CONCENTRATION; HYDROLYSIS; MODELS, CHEMICAL; PRODRUGS; SUSPENSIONS;

EID: 0036267481     PISSN: 10837450     EISSN: None     Source Type: Journal    
DOI: 10.1081/PDT-120003494     Document Type: Review

References (183)

1. Temperature dependence of bimolecular reactions associated with molecular mobility in lyophilized formulations
2. Bond cleavage reactions in solid aqueous carbohydrate solutions
3. Aspartame degradation as a function of water activity
4. Importance of glass transition temperature in accelerated stability testing of amorphous solids: Case study using a lyophilized aspirin formulation
5. Characterization of the glass transition of an amorphous drug using modulated DSC
6. The Effect of excipients on the molecular mobility of lyophilized formulations, as measured by glass transition temperature and NMR relaxation-based critical mobility temperature
7. Measurement of weak glass transitions in amorphous pharmaceutical formulations
8. Saturated salt solutions for maintaining specific relative humidities
9. Relationship between the morphological character of 5-Nitroacetylsalicylic acid crystals and the decomposition rate in a humid environment
10. 1,4-Cyclohexadiene-1-alanine (2,5-diydrophenylalanine), a new inhibitor or phenylalanine for the rat and leuconostoc dextranicum
11. Solid state dehydrogenation of L-1,4-cyclohexadiene-1-alanine hydrate to L-phenylalanine
12. The molecular basis of moisture effects on the physical and chemical stability of drugs in the solid state
13. Solid-state hydrolysis of aspirin
14. Carstensen rational presentation mode below the critical moisture content
15. Nonlinear estimation of kinetic parameters for solid-state hydrolysis of water-soluble drugs
16. Kinetics and mechanism of the solid-state decomposition of propantheline bromide
17. Topochemical decomposition patterns of aspirin
18. Solid-state stability of aspirin in the presence of excipients: Kinetic interpretation, modeling, and prediction
19. Hydrolysis of a peptide bond in neutral water
20. General base catalysis for ester hydrolysis
21. Hydrolytic stability versus ring size in lactams: Implications for the development of antibiotics and other serine protease inhibitors
22. The kinetics of hydrolysis of β-propiolactone in acid, neutral and basic solutions
23. The concurrent alkaline hydrolysis and isotopic oxygen exchange of a series of p-substituted acetanilides
24. Alkaline hydrolysis of p-nitroacetanilide and p-formylacetanilide
25. The mechanism of hydrolysis of Schiff bases derived from aliphatic amines
26. Kinetics and mechanism of N-isobutylidenemethylamine in aqueous solution
27. Theoretical basis for the detection of general-base catalysis in the presence of predominating hydroxide catalysis
28. Differentiation of nucleophilic and general base catalysis in hydrolysis of N-acetylbenzotriazole using the proton inventory technique
29. Kinetics and mechanisms of reactions of pyridines and imidazoles with phenyl acetates and trifluoroacetates in aqueous acetonitrile with low content of water: Nucleophilic and general-base catalysis in ester hydrolysis
30. Divalent metal ion catalysis in the hydrolysis of esters of picolinic acid. Metal ion promoted hydroxide ion and water catalyzed reactions
31. Biomimetically activated amino acids. Catalysis in the hydrolysis of alanyl ethyl phosphate
32. The metal-ion promoted water and hydroxide-ion catalyzed hydrolysis of Amides
33. Metal ion catalysis of anhydride hydrolysis. Metal ion promoted water and hydroxide ion catalyzed reactions of mixed cinnamic acid anhydrides
34. Metal ion-catalyzed hydrolysis of acrylate ester and amides by way of their conjugate addition adducts
35. Metal ion catalyzed hydrolysis of some β-lactam antibiotics
36. Role of metal ions in the hydrolysis reaction catalyzed by RNAase P RNA from bacillus subtilis
37. Influence of pH, temperature and buffers on cefepime degradation kinetics and stability predictions in aqueous solutions
38. Prediction of drug stability-part 2: Hydrolysis
39. A comparison of the effects of ionic strength on three preparations of acetylcholinesterase in the presence and absence of gallamine
40. Degradation study of the investigational anticancer drug clanfenur
41. Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics
42. Kinetics of hydrolysis of barbituric acid derivatives
43. Benoit synthesis, conformational study and hydrolysis of palmitoyl timolol malonate
44. Hydrolysis of succinylcholine chloride in pH range 3.0 to 4.5
45. Plotkowiak thermodynamic parameters of ampicillin hydrolysis catalyzed by hydrogen and hydroxyl ions
46. Simulation of organic reactions: From the degradation of chemicals to combinatorial synthesis
47. Computer assisted planning of organic synthesis: The second generation of programs
48. Accessing knowledge about chemical synthesis by computer
49. Sinclair a program for the logical prediction of products of organic reactions
50. Interactions of moisture with solids
51. Effect of moisture on the stability of solid dosage forms
52. The interaction of water with solid surfaces: Fundamental aspects
53. Assessment of disorder in crystalline solids
54. Calibration of water activity measuring instruments and devices: Collaborative study
55. Solid-state tyrosinase stability as affected by water activity and glass transition
56. The effect of water activity on the reaction kinetics of food deterioration
57. Influence of water activity on food product quality and stability
58. Hageman glass transition effects on solid state chemical reactions
59. Influence of water activity on enzyme reactivity and stability
60. The interactions of water with cellulose and starch derived pharmaceutical excipients
61. States of water associated with solids
62. Preformulation studies involving moisture uptake in solid dosage forms
63. Methods for the evaluation of solid state stability and compatibility between drug and excipient
64. Decomposition of aspirin in the solid state
65. Interrelationships between phase transformations and organic chemical reactivity in the solid state
66. Difference in effect of powdered and granular magnesium stearate on the solid state stability of acetylsalicylic acid
67. Chemical stability of acetylsalicylic acid in tablets prepared with different particle size fractions of a commercial brand of dicalcium phosphate dihydrate
68. Quantitative crystallinity determinations for β-lactam antibiotics by solution calorimetry: Correlations with stability
69. Changes in the physical state of model mixtures during freezing and drying: Impact on product quality
70. Borchardt solid-state chemical instability of an aspartyl residue in a model hexapeptide
71. Solid-state chemical instability of an asparaginyl residue in a model hexapeptide
72. Solution and solid-state chemical instabilities of asparaginyl and aspartyl residues in model peptides
73. Deamidation of a model hexapeptide in poly (vinylalcohol) hydrogels and xerogels
74. Effects of reducing sugars on the chemical stability of human relaxin in the lyophilized state
75. Formulation and stability of freeze-dried proteins: Effects of moisture and oxygen on the stability of freeze-dried formulations of human growth hormone
76. Temperature dependence of bimolecular reactions associated with molecular mobility in lyophilized formulations
77. The effect of bulking agent on the solid-state stability of freeze-dried methylprednisolone sodium succinate
78. An unexpected pH effect on the stability of moexipril lyophilized powder
79. Heroin: Stability and formulation approaches
80. Solid-state chemistry of a novel carbapenem with a releasable sidechain
81. Stability testing of pharmaceuticals by high-sensitivity isothermal calorimetry at 25°C: Cephalosporins in the solid and aqueous solution states
82. Acid-catalyzed inversion of sucrose in the amorphous state at very low levels of residual water
83. Nonenzymatic browning in model systems containing sucrose
84. Sucrose hydrolysis in a glassy starch matrix
85. Use of lyoprotectants in the freeze-drying of a model protein, ribonuclease A
86. Nonenzymatic browning of freeze-dried sucrose
87. How does residual water affect the solid-state degradation of drugs in the amorphous state?
88. Potential pH implications in the freeze-dried state
89. Thermomechanical properties of pharmaceutically compatible buffers at sub-zero temperatures: Implications for freeze-drying
90. Glycine crystallization during freezing: The effects of salt form, pH, and ionic strength
91. Physical state of L-histidine after freeze-drying and long-term storage
92. pH changes in buffers and foods during freezing and subsequent storage
93. Rational design of stable lyophilized protein formulations: Some practical advice
94. Effects of nonbulky DNA base damages on Escherichia coli RNA polymerase-mediated elongation and promoter clearance
95. Instability and decay of the primary structure of DNA
96. Mutagenesis by apurinic/apyrimidinic sites
97. Rate of depurination of native deoxyribonucleic acid
98. Analysis of plasmid DNA from a pharmaceutical perspective
99. Evaluation of degradation pathways for plasmid DNA in pharmaceutical formulations via accelerated stability studies
100. The development of stable protein formulations: A close look at protein aggregation, deamidation, and oxidation
101. Improving oral drug transport via prodrugs
102. β-lactamase-dependent prodrugs-recent developments
103. Targeted prodrug design to optimize drug delivery
104. Synthesis of acyclovir, ganciclovir and their prodrugs: A review
105. Metabolism-based drug design and drug targeting
106. Selective drug delivery using targeted enzymes for prodrug activation
107. L-dopa methyl ester-A candidate for chronic systemic delivery of L-dopa in Parkinson's disease
108. Esterification of acidic antiinflammatory drugs suppresses their gastrotoxicity without adversely affecting their antiinflammatory activity in rats
109. Amino-glycolic and -lactic esters as pro-drugs of amino acids
110. Corradino pharmacological study of ibuprofen guaiacal ester (AF 2259) in the rat
111. Glycerides as prodrugs. 3. Synthesis and antiinflammatory activity of [1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetyl] glycerides (indomethacin glycerides)
112. Lipoidal pro-drug analogs of various anti-inflammatory agents
113. Indomethacin esters acting as anti-inflammatory and immunosuppressive drugs
114. The behavior in gastrointestinal tract and biliary secretion of acemetacin
115. Synthesis and antiviral activity of water-soluble esters of acyclovis (9-[2-(hydroxyethoxy) methyl] guanine)
116. Prodrug approaches to enhancement of physicochemical properties of drugs. IV. Novel epinephrine prodrug
117. Synthesis and biological activity of digitoxigenin amino esters
118. Isolated perfused rabbit lung as a model for intravascular and intrabronchial administration of bronchodilator drugs. Isoproferenal prodrugs
119. Oxazepam esters. 2. Correlation of hydrophobicity with serum binding, brain penetration, and excretion
120. Oxazepam esters. 3. Intrinsic activity, selectivity, and prodrug effect
121. Lorazepam and oxazepam esters. Hydrophobicity, hydrolysis rates and brain appearance
122. Water-derivatives of 3-oxy-substituted 1,4-benzodiazepines
123. Stabilization of aspartame in water: Organic solvent mixtures with different dielectric constants
124. Aspartame-direct compression excipients: Preformulation stability screening using differential scanning calorimetry
125. Stability testing of some drugs containing ester groups: Benzyl benzoate, benzyl mandelate and propyl gallate. Part 11: Stability of drugs and preparations containing the drugs
126. Influence of sterilization temperature and pH on the stability of chlorhexidine in solutions
127. Stability of chlorhexidine solutions
128. Pharmacokinetic studies on propyl gallate metabolism in rats
129. Metabolism and cytotoxicity of propyl gallate in isolated rat hepatocytes: Effects of a thiol reductant and an esterase inhibitor
130. Hydrolysis of partially saturated egg phosphatidylcholine in aqueous liposome dispersions and the effect of cholesterol incorporation on hydrolysis kinetics
131. Alkaline hydrolysis of methyl, ethyl and n-propyl 4-hydroxybenzoate esters in the liquid and frozen states
132. Kinetic evidence for the participation of the ionized form of methyl p-hydroxybenzoate in its alkaline hydrolysis
133. Kinetics of the degradation of methyl, ethyl and n-propyl 4-hydroxybenzoate esters in aqueous solution
134. Phthalic acid ester hydrolysis under inverse phase-transfer catalysis conditions
135. Effect of disperse metal complex dyes on the hydrolysis of propylene carbonate
136. Acid-catalyzed hydrolysis of sodium lauryl sulfate
137. Osmotic drug delivery: Review of the patent literature
138. Enteric film coating using completely aqueous dissolved hydroxypropyl methyl cellulose phthalate spray solutions
139. Viscosity stability of methylcellulose solutions at different pH and temperature
140. Mechanical, water uptake and permeability properties of crosslinked chitosan glutate and alginate films
141. Novel in situ-forming opthalmic drug delivery system from alginates undergoing gelation in the eye
142. Polymer systems for biomedical applications. An overview
143. Purity and stability assessment of a semi-solid poly(ortho ester) used in drug delivery systems
144. New derivatives of polyglutamic acid as drug carrier systems
145. Solubility principles and practices for parenteral drug dosage form development
146. Formulation and administration techniques to minimize injection pain and tissue damage associated with parenteral products
147. Buffers-pH control within pharmaceutical systems
148. Protic-dipolar aprotic solvent effects on rates of bimolecular reactions
149. Solvent effects on the kinetics of alkaline hydrolysis of dimethylacetylacetone. Part I. Influence of alcohol-water mixtures
150. Effect of liposomes on the rate of alkaline hydrolysis of indomethacin and acemetacin
151. Influence of a cationic surfactant on the rate of hydrolysis of p-nitrophenyl acetate in non-buffer system
152. Hydrolysis of solubilized esters
153. The hydrolysis of propyl benzoate in aqueous solutions of surface-active agents
154. Solid state stability; Incompatibility prevention techniques
155. The effects of packaging on the stability of a moisture sensitive compound
156. Pharmaceutical blister packaging, Part 1, Rationale and materials
157. Choosing a blister material
158. Polgar ICH conditions
159. Water transport through polymers: Requirements and designs in food packaging
160. Packaging in heat-sealable materials, and the stability of drugs
161. Protection of pharmaceutical and diagnostic products through desiccant technology